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NEW AND NOTEWORTHY 5 
The peripheral chemoreflex increases both parasympathetic and sympathetic drive under chronic 6 
hypoxia. We found that this evoked brady-arrhythmias when combined with apneic periods in 7 
Lowlanders at altitude, which become relieved through supplemental oxygen. In contrast high altitude 8 
residents (Nepalese Sherpa) do not exhibit brady-arrhythmias during apnea at altitude through 9 
potential cardio-protective adaptations. The degree of bradycardia and brady-arrhythmias was related 10 
to the hypoxic ventilatory response, demonstrating that the chemoreflex plays an important role in 11 
these findings. 12 
 13 
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 20 
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ABSTRACT   28 
 29 
Peripheral chemoreflex mediated increases in both parasympathetic and sympathetic drive under chronic 30 
hypoxia may evoke brady-arrhythmias during apneic periods. We determined if: a) voluntary apnea 31 
unmasks arrhythmia at low (344m) and high (5050m) altitude, b) if high altitude natives (Nepalese 32 
Sherpa) exhibit similar cardiovagal responses at altitude; and c) if brady-arrhythmias at altitude are 33 
partially chemoreflex mediated. Participants were grouped as Lowlanders (n=14; age=27±6yrs) and 34 
Nepalese Sherpa (n=8; age=32±11yrs). Lowlanders were assessed at 344m and 5050m while Sherpas 35 
were assessed at 5050m. Heart rate (HR) and rhythm (Lead-II ECG) were recorded during rest and 36 
voluntary end-expiratory apnea. Peripheral chemoreflex contributions were assessed in Lowlanders (n=7) 37 
at altitude after 100% oxygen. Lowlanders had higher resting HR at altitude (70±15 vs. 61±15 38 
bpm;P<0.01) that was similar to Sherpas (71±5 bpm;P=0.94). High-altitude apnea caused arrhythmias in 39 
11 of 14 Lowlanders (junctional rhythm (n=4), 3° atrio-venticular block (n=3), sinus pause (n=4)) not 40 
present at low altitude and larger marked bradycardia (nadir -39±18 bpm; P<0.001). Sherpas exhibited a 41 
reduced bradycardia response during apnea compared to Lowlanders (P<0.001) and did not develop 42 
arrhythmias. Hyperoxia blunted bradycardia (nadir -10 ±14bpm; P<0.001 compared to hypoxic state) and 43 
reduced arrhythmia incidence (3 of 7 Lowlanders). Degree of bradycardia was significantly related to 44 
hypoxic ventilatory response (HVR) at altitude and predictive of arrhythmias (P<0.05). Our data 45 
demonstrates apnea-induced brady-arrhythmias in Lowlanders at altitude but not in Sherpa (potentially 46 
through cardio-protective phenotypes). The chemoreflex is an important mechanism in genesis of brady-47 
arrhythmias and the HVR may be predictive for identifying individual susceptibility to events at altitude.   48 
 49 
Key Words:  Hypoxia; Arrhythmia; Apnea; Sherpa; Chemoreflex 
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INTRODUCTION 52 
It has been traditionally shown that efferent sympathetic and vagal outflow to the heart is reciprocal, 53 
through which increased activation of one pathway sees a respective decrease in the other (17). As such, 54 
the variation of cardiac sinus conduction is controlled through the balance between neural outflows in 55 
healthy populations.  Concurrent increases in both pathways can occur under specific circumstances, and 56 
has previously referred to as cardiac  “autonomic conflict” (29). This has previously been previously 57 
reported during periods of considerable autonomic stress  (e.g. cold water submersion) due to conflicting 58 
activation of both sympathetic and parasympathetic pathways, ultimately promoting cardiac 59 
arrhythmogenesis in healthy individuals (8, 33). In addition, conflict can be seen to some degree in 60 
clinical populations suffering from sleep apnea, where elevated chemoreflex gain during apneic periods 61 
being is linked to both hypertensive and bradycardia responses (24, 30). Yet the degree of conflict can be 62 
considered minimal, with no previous accounts of arrhythmogenesis being noted in healthy populations 63 
exhibiting normal chemoreflex function during apnea (e.g. volitional breath holding).   64 
 65 
 Heightened chemoreflex activity under chronic hypoxia results in a concurrent increase of efferent 66 
peripheral sympathetic nerve activity and cardiac vagal tone (9).  However these increases are normally 67 
dampened by the inhibitor influence of pulmonary stretch receptors, ultimately blunting sympathetic 68 
outflow to heightened chemoreflex stress (19, 28, 31).  As such, there is limited electrocardiographic 69 
evidence that suggests chronic hypoxia exposure leads to incidences of bradycardic arrhythmia within 70 
healthy individuals during sleep (4).  The peripheral chemoreflex has been implicated specifically in these 71 
cases as the changes in heart rate observed appear correlated to the ventilatory response to acute hypoxia 72 
(22). Thus, there is a mechanistic basis for hypothesizing that chemoreflex sensitization during 73 
acclimatization at altitude (10) may promote autonomic conflict and potential bradycardic arrhythmic 74 
events during periods of sleep-related apnea.  The use of voluntary apnea during chronic altitude exposure 75 
is therefore a relevant experimental model to investigate autonomic cardiac function independent of 76 
underlying comorbidities.   77 
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 78 
Recently, we conducted a high altitude research expedition to 5050m in the Himalayan mountain 79 
range of Nepal.  Our goal was to study autonomic function during chronic hypoxic exposure in 80 
Lowlanders. We contrasted these data with high altitude natives (Nepali Sherpa) to examine whether they 81 
would have similar vagal drive as Lowlanders, despite generations of residency at altitude. Our study was 82 
designed to experimentally investigate a) if voluntary apnea would unmask vagal mediated bradycardia or 83 
conduction abnormalities during wakefulness at altitude (5050m), b) the degree to which the peripheral 84 
chemoreflex plays a role in the susceptibility to bradycardic arrhythmia at altitude and c) if low and high 85 
altitude natives exhibit similar cardiovagal responses to apnea. Based on previous findings we 86 
hypothesized that voluntary apnea in the awake state would experimentally unmask heightened vagal 87 
activity and indications of autonomic conflict in Lowlanders at altitude, characterized by bradycardia and 88 
arrhythmias.  89 
 90 
METHODS 91 
 92 
Study Participants 93 
Fourteen Lowlanders (2 female; age=27±6yrs) and 8 highland Nepalese Sherpas (age=32±11yrs) from 94 
the Khumbu region of Nepal participated after providing informed written consent.  All procedures were 95 
explained in English and Nepalese and approved by the University of Alberta Biomedical Research Ethics 96 
Board, the University of British Columbia Clinical Research Ethics Board, and the Nepal Health Research 97 
Council (Pro00064195) in compliance with the declaration of Helsinki.  Health-history screening was 98 
negative for any pre-existing cardiovascular, respiratory or neurological disorders. Four Sherpa were 99 
current smokers (0.42±0.7 pack years). 100 
 101 
 102 
 103 
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Resting Baseline and Apnea Protocol 104 
Pre-expedition testing (Lowlanders) was conducted at 344m (Kelowna, Canada).  After flying to 105 
2840m participants followed a conservative ascent profile (9-10 days) to the EV-K2-CNR research 106 
facility (5050m; Nepal). Two Lowlanders were administered medication for treatment of altitude illness 107 
during ascent (a single dose of acetazolamide (125mg) or dexamethasone), but were tested following a 108 
minimum 48hr washout period. Sherpa were tested on days 1-4 and Lowlanders were tested after 4-10 109 
days at 5050m. Both Sherpa and Lowlanders exhibited similar resting peripheral oxygen saturation (SpO2, 110 
82% and 83% respectively) at 5050m. 111 
 112 
Participants were tested in the supine position.  ECG (Lead II) and arterial blood pressure (finger 113 
photoplethysmography; Finometer Pro, Finapres Medical Systems, Netherlands) were collected 114 
continuously at 1KHz (ADInstruments, Chart Pro v8.3.1).  Brachial arterial pressure waveform was back 115 
calibrated through return to flow (RTF) correction confirmed against manual brachial measurements.   116 
Mean (MAP), systolic (SBP) and diastolic (DBP) pressures were calculated on a beat-by-beat basis from 117 
the calibrated pressure waveform. Beat-by-beat cardiac output (CO) was calculated using the Model Flow 118 
algorithm and used to calculate total peripheral resistance (TPR = MAP/CO).  SPO2 was continually 119 
assessed (pulse oximetry; Nellcor, Medtronics,USA). Following 10 minutes of quiet baseline measures 120 
participants were instructed to perform an end-expiratory apnea (at functional residual capacity). An 121 
investigator paced participants’ breathing and signaled when to initiate apnea.  Participants wore a nose 122 
clip and were instructed to “hold their breath for as long as possible”. The role of the peripheral 123 
chemoreceptors was assessed in seven Lowlanders by repeating apnea at altitude after 1-2 min of pre-124 
breathing 100% oxygen.  In addition, individual hypoxic ventilatory responses (HVR; 125 
ΔVentilation/ΔSpO2) at altitude were recorded in a subset of Lowlanders within our study (n=11; 1 126 
female) and Sherpa (n=6) by breathing a fixed FiO2 (~16%) for five minutes while at 5050m. However, 127 
this HVR response was only measured once and not during successive periods while at altitude. We were 128 
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unable to obtain the HVR response in three of the fourteen Lowlanders and two of the eight Sherpa. 129 
These HVR measures were performed independent of the study, though they were at similar time points.  130 
 131 
Data and Statistical Analysis 132 
 In order to determine if voluntary apnea unmasks autonomic conflict in Lowlanders and Sherpa at 133 
altitude; values were calculated at two periods within each group (Lowlanders, lowlanders with 134 
supplemental oxygen, and Sherpa) and condition (low and high altitude). Baseline values were calculated 135 
over 5 minutes of spontaneous breathing. Electrophysiological characteristics (waveform amplitudes, 136 
durations and intervals) of the ECG were assessed during the 30 sec immediately preceding apneas; 137 
cardiac cycles (15-45) were over-laid, aligned with the R-wave and the aggregate was analyzed using 138 
automated software (Chart Pro 8.3.1).  To account for variation in apnea duration, cardiovascular data 139 
from the final 10 cardiac cycles of each apnea were analyzed. A cardiologist (SVD) identified and 140 
classified conduction abnormalities from ECG waveforms from the 3 beats immediately preceding and 3 141 
beats following apnea breakpoint.  142 
 143 
Baseline heart rate variability (HRV) was calculated during 5 minutes to contrast the relative 144 
contribution in sympathetic and parasympathetic activation between low and high altitude, and under 145 
supplemental oxygen at high altitude. HRV was analyzed using commercially available software 146 
(ADI, MLS310/8 HRV, Colorado Springs, CO, USA). Frequency domain analyses included 147 
spectrum analysis of very low (VLF; 0-0.04 Hz), low (LF; 0.04-0.15 Hz), and high (HF; 0.15-148 
0.40 Hz) frequency bands. Temporal domain analyses included the standard deviations of the 149 
deviations between successive RR intervals (SDNN) and Root Mean Square of the Successive 150 
Differences (RMSSD). Total power was calculated as the variance of all NN intervals. The ratio 151 
of LF to HF power (LF/HF) was also used. 152 
 153 
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Statistical analyses was performed using Sigma Stat 3.13 (Systat Software, Chicago, IL). Results are 154 
reported as mean ± standard deviation. Differences in cardiovascular data between conditions (low vs. 155 
high vs. high+ oxygen) and between groups (Lowlanders vs. Sherpa) were assessed using pre-planned 156 
contrasts (paired and unpaired T-tests).  Mann-Whiney tests were run in incidences of non-normal 157 
distributions.  Differences in incidence of arrhythmias between conditions in Lowlanders were assessed 158 
using McNemar’s test for paired dichotomous data.  In order to correct for multiple comparisons (c), the a 159 
priori alpha (α, 0.05) was adjusted (α’) using the experiment-wise error rate (αe)  (15, 32):  160 
 161 
 162 
 163 
 164 
 165 
Relationships between measures were assessed using Pearson correlations.  Receiver operating 166 
characteristic (ROC) curve analysis was performed to assess the specificity and sensitivity of an 167 
individual’s HVR to predict the susceptibility to arrhythmia during apnea at altitude.   168 
 169 
RESULTS 170 
All 14 Lowlanders were successfully tested at 344m and 5050m. No sex differences were present 171 
between the 2 females in the Lowlander group. Prior to testing one Lowlander was categorized as having 172 
mild acute mountain sickness at altitude (Lake Louise score 3), but no other participants exhibited 173 
symptoms of illness.  174 
 175 
Group characteristics and cardiovascular function for each condition are reported in Table 1.  HR 176 
increased in Lowlanders at high altitude (p<0.05 vs. low altitude); becoming similar to Sherpas. SBP, 177 
DBP, MAP, CO, and TPR were unchanged in Lowlanders at high altitude (SBP P= 0.060; DBP P= 0.782; 178 
MAP P=0.901; CO P=0.159 and; TPR P=0.056) and no different than Sherpas (SBP P= 0.786; DBP P= 179 
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0.287; MAP P=0.641; CO P=0.581 and; TPR P=0.789). High altitude HVR was not different between 180 
Lowlanders (1.11± 1.78 L/min/% desaturation) and Sherpa (0.28± 0.16 L/min/ % desaturation; P=0.317).  181 
This remained non-significant even after accounting for one apparent Lowlander “outlier” with a high 182 
HVR (6.2 L/min/ % desaturation; P=0.242).  183 
 184 
 185 
Ascent to altitude saw a shortening of the P-R interval (P<0.001) and P-wave duration (P<0.05), QRS 186 
complex widening (P<0.001), QTc prolongation (P<0.001) and P-wave amplitude depression (P<0.001) 187 
in Lowlanders (Table 2).  Sherpas also exhibited widened QRS complexes (P<0.001) and longer QTc 188 
(P<0.05) at altitude compared to Lowlanders at low altitude (Table 2).  The incidence of arrhythmia at 189 
rest was low in all groups and conditions (Table 3). One Lowlander exhibited periodic premature 190 
ventricular contractions during rest at both altitudes, but the incidence remained low (<2/min) and 191 
unchanged between altitudes.  Upon accent to altitude one Lowlander developed persistent junctional 192 
rhythm that was not relieved with oxygen. No arrhythmias were noted in Sherpa at rest.  193 
 194 
Lowlanders saw no difference in indices of HRV (SDNN, RMSDD, and total power) between 195 
low and high altitude with exception to RRI, which became significantly decreased (1157± 240ms versus 196 
979±208 ms; P<0.001) at high altitude. However, oxygen supplementation did not relieve SDNN, 197 
RMSDD, total power, and RRI at altitude. Sherpas did not exhibit any difference in HRV measures to 198 
Lowlanders at high altitude. For all groups/altitude there was no difference in frequencies (VLF, LF, and 199 
HV) and total power. However, Lowlanders exhibited a significant increase in the LF/HF ratio at high 200 
altitude (P<0.05), while both the supplemental oxygen group and Sherpas LF/HF ratio was not different at 201 
altitude. 202 
 203 
 204 
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Responses to Voluntary Apnea at Low Altitude  205 
At low altitude, Lowlander SpO2 was 98±1% prior to apneas but was not obtained during or 206 
immediately post-apnea.  Lowlanders had an apnea duration of 30.4± 11.1s (range 15-74s) which resulted 207 
in a modest bradycardia response (-10±15 bpm; P<0.001) (Figure 1).  No changes in ECG parameters 208 
were noted during apnea at low altitude, although 3 of the 14 Lowlanders developed arrhythmia 209 
(premature atrial contractions, atrial bigeminy, and non-conducted sinus beat; Table 3). 210 
 211 
Responses to Voluntary Apnea at High Altitude  212 
At high altitude, resting SpO2 was similar in Lowlanders (82±3%) and Sherpa  (83±4%; P=0.933).  213 
Apnea resulted in further desaturation of Lowlanders (nadir 78±7%) and Sherpa (nadir of 75±5%; 214 
P=0.344 versus Lowlanders at altitude). Apnea duration was also reduced in Lowlanders [15.4±5.3 s 215 
(range 9-27s), P<0.001 compared to low altitude] that was similar to Sherpa (15.8±2.6; Range 12-19s). 216 
 217 
Lowlander apneas saw magnified bradycardia at high altitude (-39± 18 bpm; P<0.001 versus low 218 
altitude).   In contrast, Sherpa had a reduced extent of bradycardia during apnea (-7± 10 bpm; P<0.001 219 
versus Lowlanders). Despite bradycardia blood pressure progressively rose in Lowlanders to a peak MAP 220 
at low altitude (112± 19mmHg; P<0.001 versus baseline) and high altitude (100±21 mmHg P< 0.01 221 
versus baseline). Peak blood pressure response was similar in Sherpa (100± 12 mmHg; P=1.035 versus 222 
Lowlanders at altitude) (Figure 1). Between rest and apnea only QTc duration was significantly reduced 223 
(P<0.01) in Lowlanders. Apneas at high altitude resulted in a prolongation of the QRS (P<0.01) and PR 224 
intervals (P<0.05) while P and T wave amplitudes were depressed (P<0.001) in Lowlanders.  Sherpas and 225 
Lowlanders exhibited mostly similar ECG values during apnea at altitude. However, Sherpa P-wave 226 
duration was significantly prolonged (P<0.05) compared to Lowlanders. 227 
 228 
At high altitude there was a greater incidence in arrhythmias during apnea in Lowlanders (11 of 14; 229 
P<0.05) compared to low altitude apnea. Identified arrhythmias included sinus pause/arrest, junctional, 230 
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and 3° atrio-venticular block (Figure 2; Table 3).  In contrast, no abnormalities were apparent during 231 
apnea in Sherpas, despite no differences in the duration of apnea or degree of desaturation when 232 
compared with lowlanders at altitude.   233 
 234 
As HVR was similar between groups (see above), including the one female participant, data were 235 
combined to assess the relationship between HVR and heart rhythm.  The gain of the bradycardic 236 
response during apnea across groups was correlated with HVR (Figure 3).  Two Lowlanders were 237 
identified as statistical outliers using studentized residuals; however, the relationship remained significant 238 
when these individuals were either included or removed from the analysis (Figure 3). When data were 239 
grouped based on the presence or absence of arrhythmia during apnea, those individuals exhibiting apneas 240 
had significantly higher HVRs (Median 0.66 L/min) vs. those that did not exhibit arrhythmias (Median 241 
0.26, P<0.02; Figure 4a).  ROC analysis further indicated that HVR was significantly predictive of the 242 
incidence of arrhythmia during apnea (AUC = 0.86, P<0.05; Figure 4b) with a sensitivity of 75% and 243 
specificity of 78% when using an optimized HVR cutoff of 0.40 L/min (Figure 4c). However, there was 244 
no relationship between HVR and the magnitude of bradycardia during apnea (R2= 0.08). 245 
 246 
Influence of Supplemental Oxygen to Apneic Response at High Altitude  247 
 Supplemental oxygen was administered to 7 out of the 14 Lowlanders at high altitude prior to 248 
voluntary apnea.  This increased initial SpO2 from 82± 3 % to 96± 1 % (P<0.001) prior to apnea and 249 
reduced resting heart rate (62± 10 bpm; P<0.05 versus altitude).  Apnea duration was prolonged (67.0± 250 
45.2 s; P<0.01 versus euoxic apnea) following oxygenation.  Oxygenation significantly blunted apnea 251 
related bradycardia (Figure 1; P<0.05) but increased associated peak in MAP (117± 16mmHg; P<0.05).  252 
Supplementation of oxygen returned R-wave amplitude to low altitude values and the incidence of 253 
arrhythmia was significantly reduced compared to euoxic apnea (3 of 7 Lowlanders, p<0.05; Table 3).  254 
 255 
 256 
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DISCUSSION 257 
In the current study we have demonstrated that through the use of voluntary apnea at altitude, there 258 
exists considerable underlying vagal and sympathetic drive in Lowlanders as marked by significant 259 
bradycardia and incidence of brady-arrhythmias. In contrast, Sherpas exhibited a less pronounced 260 
bradycardia during apnea and an absence of arrhythmias.   Using supplemental oxygen we further 261 
demonstrated that the augmented bradycardia and arrhythmias observed in Lowlanders were specifically 262 
related to the peripheral chemoreflex. This was also supported by a significant relationship between the 263 
participant specific HVR and the degree of bradycardia occurring during apnea.  Furthermore, ROC 264 
analysis indicated that heightened HVR was significantly predictive of the susceptibility to high altitude 265 
arrhythmias during apnea. 266 
 267 
At altitude Lowlanders exhibited shorter P wave duration and PR Interval; as well as enlarged P and R 268 
wave amplitudes, suggesting an elevated sympathetic drive as seen previously (11, 14).  In clinical 269 
contexts shortening of P and PR intervals is associated with increased risk of atrial fibrillation (1, 26). 270 
Despite changes in ECG conductance, arrhythmias during baseline were not observed in either 271 
Lowlanders or Sherpa. Previous accounts altitude related arrhythmias in Lowlanders have been reported.  272 
These have been primarily documented during periods of physical exertion after rapid accent (3) or 273 
during sleep (4). Similar to our findings, these events were also associated with flattened T-wave 274 
amplitudes and p-wave shortening(3).  Recently, Woods et al.  (34) noted the presence of symptomatic 275 
sinus tachycardia at altitude (n=2) during periods of strenuous exercise via implantable loop recorder; 276 
where Brooks et al. (4) also noted arrhythmias during periods of exertion periods at altitude in 16 277 
Lowlanders using continuous ECG monitoring. In both reports, arrhythmia incidence was increased at 278 
higher altitudes (5000-7550m) as well as with longer exposure periods (4, 34). Both our data and these 279 
previous findings suggest high altitude to be a “pro-arrhythmia” environment, where the influence of 280 
hypoxia may be compounded further during periods of stress. Although we did not obtain continuous 281 
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ECG monitoring through the study; our findings agree with the presence of arrhythmias during periods of 282 
heightened stress. 283 
 284 
Previous studies show increased periodic breathing and central apnea at altitude in Lowlanders (2, 5, 285 
27); as well as associated periods of bradycardia (16, 20, 22, 27) and arrhythmia (6, 16, 20). Thus, the 286 
current study utilized voluntary apnea to characterize the mechanisms of altitude related bradycardia and 287 
arrhythmia in Lowlanders at rest. The significant bradycardia as well as the development of arrhythmias 288 
(11 of 14 Lowlanders) during apnea is indicative of heightened sympathetic and parasympathetic 289 
innervation of the heart at altitude (9, 17, 25).   Although the relationship sympathetic and 290 
parasympathetic control is often considered reciprocal, when both innervations are concurrently elevated 291 
the heart experiences what has previously been termed as “autonomic conflict”. The occurrence of cardiac 292 
arrhythmias during cold-water immersion has been attributed to this conflict (29) when high sympathetic 293 
(cold shock response) and parasympathetic (mammalian diving reflex) activity occurs. As classically 294 
described, the primary cardiovascular consequences of peripheral chemoreceptor activation are 295 
concurrently elevated sympathetic and parasympathetic activity (9). Yet under eupneic conditions 296 
hypoxia engages pulmonary reflexes (via the hypoxic ventilatory response) that inhibit both 297 
parasympathetic (9) and sympathetic activity (19, 28, 31). The degree of chemoreflex sensitivity and its 298 
direct relationship to sympathetic augmentation at altitude is not fully understood. Despite this, earlier 299 
works have demonstrated that the augmentation of sympathetic activity under acute hypoxia exposure is 300 
driven through heightened peripheral chemoreflex activation (23, 35). In the current study we have 301 
demonstrated a similar “autonomic conflict” that is unmasked during apnea and mediated via the 302 
peripheral chemoreflex. Firstly, we showed that the bradycardia associated with apnea at altitude was 303 
correlated with the hypoxic ventilatory response.  Secondly, oxygen administration prior to apnea at 304 
altitude eliminated bradycardia and reduced the incidence of arrhythmia to the same level as observed at 305 
low altitude.  306 
 307 
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Although Sherpas had a similar breath hold duration and resting arterial oxygen saturation; they 308 
did not exhibit significant bradycardia or any arrhythmias.  Previous data from native Tibetans indicate a 309 
normal ECG compared Han residents who had migrated during childhood to high altitude (13).  We saw 310 
that breath holding generated arrhythmias in most Lowlanders but not Sherpa.  Thus, these findings 311 
suggest that Sherpa exhibit an altered cardiac response to hypoxic stress. However, it is unclear what the 312 
specific nature of the adaptation that might be present.  We do not believe this is related to differences in 313 
chemoreflex sensitivity as our findings are consistent with recent data indicating Sherpas to have similar 314 
chemoreflex sensitivity to acclimatized Lowlanders (7, 12, 36).  Yet when Lowlanders and Sherpa were 315 
considered together, we found that high altitude HVR was significantly related to the normalized 316 
bradycardic response to high altitude apnea.   Previously, Masuyama et al. (21) observed a significant 317 
relationship between low altitude HVR and high altitude sleep related (normalized) bradycardia.  These 318 
previous data are intriguing as the relationship they demonstrate is apparent across conditions (low vs. 319 
high altitude) and sleep state (awake vs. sleep).  This would suggest a robust predictive utility of low 320 
altitude HVR.  In keeping with this, we demonstrated that high altitude HVR was significantly predictive 321 
of arrhythmias during apnea at altitude and therefore potentially useful as a predictor for risk of high 322 
altitude arrhythmia. 323 
 324 
Considerations 325 
 The current study was apart of a larger research expedition to the Himalayan Range in Nepal and 326 
involved several independent studies examining vascular, cerebral auto-regulatory, neuromuscular, and 327 
autonomic function between Lowlanders and Sherpa. As such, certain time-dependent and technical 328 
limitations exist with regards to testing both Lowlanders and Sherpa at altitude. One limitation was the 329 
inability to repeat the supplemental oxygen trial within Sherpa. Sherpa were initially tested at 5050m and 330 
soon followed by Lowlanders. Yet significant arrhythmic events were only noted in Lowlanders at 331 
5050m. Following several examples of arrhythmias within Lowlanders we attempted to address the 332 
potential chemoreflex contribution though supplemental oxygen. However, Sherpa exhibited neither 333 
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considerable bradycardic responses nor arrhythmias during apnea. Therefore, we believe that 334 
supplemental oxygen would not have produced any considerable difference in cardiovagal responses 335 
during apnea.   336 
 337 
 We demonstrate a relationship between the HVR and degree of bradycardic response at altitude. 338 
However, we acknowledge that two individuals with high HVRs (statistically identified as outliers in 339 
relation to the rest of our participants) appear to weight this relationship.   However, even if these two 340 
participants were removed, there still existed a significant relationship between HVR and bradycardic 341 
response (see figure 3).  We acknowledge that our measure of HVR may exhibit some degree of 342 
ventilatory suppression through respiratory induced alkalosis, thus further minimizing central 343 
chemoreceptor activation. This limitation within our HVR measure should be considered during 344 
interpretation of results. However, our specific goal was to assess peripheral chemoreceptor contributions 345 
within a high altitude field setting.  Due to the nature of the technique that was utilized for determining 346 
HVR (measuring the ventilatory response to continuous 16% FiO2 at 5050m) without successive 347 
measurements; it would be recommended that utilizing HVR for predicting bradycardic events should be 348 
investigated further to confirm the present findings.   349 
 350 
Conclusion 351 
 Our results suggest increased parasympathetic activity and sympathetic drive at altitude promote  352 
“autonomic conflict” during apnea. Thus, potential conflict may promote both cardiac changes and 353 
arrhythmia development in Lowlanders that travel to higher elevations for work or pleasure. Since high 354 
altitude HVR appears to be predictive of arrhythmia incidence; further evaluation of low altitude HVR 355 
should be evaluated for predicting the susceptibility of to high altitude brady-arrhythmia.  The lack of 356 
arrhythmias in Sherpa suggests an adaptive mechanism, though it is unclear if the mechanism behind this 357 
response is due to generational adaptation. 358 
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FIGURE LEGENDS 482 
FIGURE 1. Responses to apnea in Lowlanders at 344m (n.14; black circle), Lowlanders at 5050m (n.14; 483 
white circle), Lowlanders + O2 at 5050m (n.7; blue circle), and Sherpa at 5050m (n.8; red circle). Panel 484 
A, Absolute bradycardia response to apnea. Panel B, Percentage change of bradycardic response to apnea.   485 
A significant bradycardia response was observed in Lowlanders at high (but not) low altitude.  Apnea 486 
after 100% oxygen eliminated bradycardia in Lowlanders.  Sherpa did not exhibit bradycardia during 487 
apnea at altitude. Panel C, Absolute pressor response during apnea. Panel D, Percentage change of 488 
pressor response during apnea. All data has been aligned to break-point and the last 10 cardiac cycles 489 
have been plotted.  The mean nadir/peak responses are also identified.  *Lowlanders at high altitude 490 
significantly different from all other groups, P < 0.05; † Significant difference between Lowlanders at low 491 
altitude vs. Lowlanders at high attitude, P<0.05; ‡ Significant difference between Lowlanders at low 492 
altitude and Sherpa, P<0.05; § Significant difference between Lowlanders + Oxygen (n.7) at altitude and 493 
Sherpa, P<0.05; ║ Significant difference between Lowlanders + Oxygen and Lowlanders (without 494 
oxygen) at altitude, P<0.05. 495 
FIGURE 2: Raw data demonstrating apnea induced arrhythmia at altitude. Examples of ECG tracings 496 
from the same male participant during apnea at low (top) and high altitudes (bottom).  Apnea at altitude 497 
exhibited arrhythmic events, such as  3° heart block (see inset bottom right) 498 
FIGURE 3: Correlation analysis between the normalized bradycardic response to apnea and hypoxic 499 
ventilatory response at altitude across groups.  Closed circles represent Lowlanders (n.14) and open 500 
circles represent Sherpa (n.8). Two lowlanders were identified at statistical “outliers” (red symbols) based 501 
on studentized residuals.  However, a significant relationship was also maintained if these participants 502 
were excluded (inset).  The dashed lines and dotted lines represent the linear regressions and 95% 503 
confidence intervals respectively.  504 
 505 
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FIGURE 4: Hypoxic ventilatory response was higher in individuals who developed arrhythmias during 506 
apnea (A).  Receiver operating curve analysis indicated that the hypoxic ventilatory response was 507 
significantly predictive of the incidence of arrhythmia at altitude (B).  When an optimal cut-off was 508 
determined (0.40 L/min/% desaturation), the hypoxic ventilatory response was predictive of arrhythmias 509 
with a sensitivity of 75% and specificity of 78%. 510 
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TEXT TABLES512 
Table 1: Demographic, cardiovascular, and sympathetic function in Lowlanders and Sherpa at low and 
high altitudes.  
 LOWLANDERS SHERPA 
 
334m 
(n =14) 
5050m 
(n =14) 
5050m +Oxygen 
(n =7) 
5050m 
(n =8) 
Subject Demographics     
Age (years) 27± 6 27± 6 30± 8  32± 13 
Height (m) 1.77± 0.8 1.77± 0.8    1.79± 0.06  1.68± 0.08 
Weight (kg)   72.2± 10.1 69.4± 8.6    69.3± 10.3  63.7± 10.1 
BMI (kg/m2) 23.1± 2.8 22.2± 2.5  21.5± 2.9         22.8± 3.5 
 
Resting Cardiovascular 
Function 
    
Heart Rate (bpm)   61± 15     70± 15*     62± 10*   71± 5‡ 
SPO2 (%) 98± 1 82± 3    96± 1 † 83± 4 
Systolic Pressure (mmHg)     119± 9 113± 13        113± 8          111± 9 
Diastolic Pressure (mmHg) 66± 7   70± 10 71± 8 65± 8 
Mean Pressure (mmHg) 84± 8   86± 11 89± 7 84± 9 
Cardiac Output (L/min) ♦   5.9± 1.8   5.5± 1.4   5.1± 1.1   6.0± 1.7 
Total Peripheral Resistance♦ 15± 4 17± 4 19± 7 16± 7 
♦ Values calculated using Model Flow. 
* Significantly different from Lowlanders tested at low altitude (334m); p <0.05. 
† Significantly different from Lowlanders tested at high altitude (5050m); p<0.05.  
‡Significantly different from Lowlanders during hyperoxia (5050m + Oxygen); p<0.05. 
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 513 
514 
Table 2: Electrocardiogram measurements made in Lowlanders and Sherpa at low and high altitudes 
during rest and apnea.  
 LOWLANDERS SHERPA 
 
334m 
(n =14) 
5050m 
(n =14) 
5050m +Oxygen 
(n =7) 
5050m 
(n =8) 
REST     
P-wave duration (ms)   96± 10   77± 20*   87± 12    97± 16† 
P-wave amplitude (mV)   0.16± 0.05 0.14± 0.04   0.14± 0.06      0.11± 0.02*‡ 
PR-Interval (ms) 169± 19 124± 27*  146± 51  158± 38† 
QRS duration (ms)   71± 14    121± 3*  119± 6 * 120± 1* 
▲QTc (ms)      398± 26 456± 28*    449± 23 *     408± 15†‡ 
R-wave amplitude (mV)   1.76± 0.70 1.24± 0.60       1.49± 0.45 *     1.19± 0.22* 
T-wave amplitude (mV)   0.49± 0.19   0.28± 0.14*      0.39± 0.19 *     0.36± 0.15* 
     
APNEA     
P-wave duration (ms)  96± 20      74± 27     68± 22       68± 34†‡ 
P-wave amplitude (mV)   0.15± 0.05   0.10± 0.06*     0.10± 0.06*     0.09± 0.06* 
PR-Interval (ms) 163± 31 128± 26* 151± 55 157± 37 
QRS duration (ms)  74± 13    119± 4* 117± 5*   113± 10* 
▲QTc (ms)      398± 34   410 ± 33§   417± 31*   465± 51‡ 
R-wave amplitude (mV)  1.67± 0.79   1.45± 0.74     1.65± 0.60*   1.25± 0.34 
T-wave amplitude (mV)  0.48± 0.19   0.32± 0.18*    0.40± 0.28   0.37± 0.13 
All measurements were taken using a standard lead II configuration. Measurements during apnea were 
taken from the 10 cardiac cycles prior to volitional breakpoint 
▲Framingham correction (QT+0.154*(1-RR). 
* Significantly different from Lowlanders tested at low altitude (334m); p <0.05. 
† Significantly different from Lowlanders tested at high altitude (5050m); p<0.05.  
‡ Significantly different from Lowlanders during hyperoxia (5050m +Oxygen); p<0.05. 
§ Significantly different from rest within the same condition/group; p<0.05. 
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Table 3: ECG conduction abnormalities identified at rest and during voluntary apnea.  
 LOWLANDERS SHERPA 
 334m 
(n =14) 
5050m 
(n =14) 
5050m +Oxygen 
(n =7) 
5050m 
(n =8) 
ABNORMALITIES IDENTIFIED AT REST     
Premature Ventricular Contractions (< 2/min) 1 1 1 --- 
Junctional Rhythm --- 1 1 --- 
ABNORMALITIES ASSOCIATED WITH 
APNEA* 
    
Atrial Bigeminy --- --- 1 --- 
Premature Atrial Contractions 1 --- --- --- 
Ectopic Atrial Rhythm 1 --- --- --- 
Non-conducted Sinus Beat 1 --- --- --- 
Non-conducted sinus beat / Junctional Escape  --- 1 --- --- 
Sinus Pause/Arrest --- 1 --- --- 
Sinus Pause/Arrest with Junctional Escape --- 2 --- --- 
Sinus Pause with Junctional Rhythm --- 1 --- --- 
Sinus Arrest with Junctional Rhythm --- 3 1 --- 
3º A-V Block --- 3 1 --- 
ECG assessment carried out by cardiologist (SVP) who was blinded to group and condition.  Premature 
ventricular contractions were observed at rest in the same individual under all conditions; the rate of occurrence 
did not change with condition.  One individual developed persistent junctional rhythm at altitude, this persisted 
during the oxygen administration. 
* All conduction abnormalities associated with voluntary apnea occurred immediately preceding or following (< 3 
beats) break-point. 
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FIGURE 3. 
  Hypoxic Ventilatory Response (L/min/% Desaturation)
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FIGURE 4 
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